SCHEMBL3022599

SCHEMBL3022599

O=C(O)c1ccccc1OS[Hg]

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.55
ALDH1A1 P00352 9/20 0.55
HSD17B10 Q99714 6/20 0.55
HPGD P15428 6/20 0.55
HMGB1 P09429 2/20 0.55
NAPRT Q6XQN6 2/20 0.55
ESR1 P03372 1/20 0.55
ITGB3 P05106 1/20 0.55
ITGA2B P08514 1/20 0.55
TSHR P16473 1/20 0.55
GGT1 P19440 1/20 0.55
PTGS1 P23219 1/20 0.55
PTGS2 P35354 1/20 0.55
BLM P54132 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPT P10636 2/20 0.53
USP2 O75604 1/20 0.53
PDE3A Q14432 1/20 0.53
ALOX15 P16050 1/20 0.52
HTT P42858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11108804 0.98 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL144897 0.85 KDM4E (0.57) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL29402606 0.85 KDM4E (0.57) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL27705464 0.82 KDM4E (0.53) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL212177 0.82 KDM4E (0.58) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL9289450 0.80 KDM4E (0.52) KDM4EALDH1A1HSD17B10HPGDHMGB1
Ammonia Solution, Strong SCHEMBL28040604 0.80 KDM4E (0.56) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL11358522 0.79 KDM4E (0.56) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL3682302 0.79 KDM4E (0.59) KDM4EALDH1A1HSD17B10HPGDHMGB1
SCHEMBL446113 0.78 HTT (0.77) KDM4EALDH1A1HSD17B10HPGDHMGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0238657-B1 ANTIVIRAL IMMUNOTHERAPEUTIC AGENT AND PREPARATION THEREOF VETREPHARM RESEARCH, INC. (US) 1992-03-11 EP claimed
US-4946853-A Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method ELAN TRANSDERMAL LIMITED (IE) 1990-08-07 US claimed
EP-0141732-B1 COSMETIC CLEANSING COMPOSITION, PARTICULARLY EYE MAKE-UP REMOVER L'OREAL (FR) 1988-05-11 EP claimed
EP-0141732-A2 Cosmetic cleansing composition, particularly eye make-up remover L'OREAL (FR) 1985-05-15 EP claimed
US-20240108730-A1 CORTICOSTEROID COMPOSITIONS VIROPHARMA BIOLOGICS LLC (US) 2024-04-04 US disclosed
US-11931227-B2 Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding COOK MEDICAL TECHNOLOGIES LLC (US) 2024-03-19 US disclosed
US-20230255984-A1 CORTICOSTEROID COMPOSITIONS VIROPHARMA BIOLOGICS LLC (US) 2023-08-17 US disclosed
US-11357859-B2 Compositions for the treatment of gastrointestinal inflammation VIROPHARMA BIOLOGICS LLC (US) 2022-06-14 US disclosed
EP-3970726-A1 METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION ViroPharma Biologics LLC (US) 2022-03-23 EP disclosed
EP-3574914-B1 CORTICOSTEROID COMPOSITIONS VIROPHARMA BIOLOGICS LLC (US) 2021-12-29 EP disclosed
EP-2585075-B1 METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION MERITAGE PHARMA INC (US) 2021-08-18 EP disclosed
EP-2968651-B1 ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONS COOK MEDICAL TECHNOLOGIES LLC (US) 2020-10-21 EP disclosed
US-5135480-A Transdermal drug delivery device ELAN TRANSDERMAL LIMITED (IE) 1992-08-04 US disclosed
EP-0484186-A1 Formulations and their use in the treatment of neurological diseases ELAN CORPORATION, Plc (IE) 1992-05-06 EP disclosed
US-4946853-A Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method ELAN TRANSDERMAL LIMITED (IE) 1990-08-07 US disclosed
EP-0325843-A2 Pharmaceutical formulations for preventing drug tolerance ELAN CORPORATION PLC (IE) 1989-08-02 EP disclosed
EP-0289342-A2 Method for the treatment of withdrawal symptoms associated with smoking cessation and preparations for use in said method ELAN TRANSDERMAL LIMITED (IE) 1988-11-02 EP disclosed
EP-0141732-B1 COSMETIC CLEANSING COMPOSITION, PARTICULARLY EYE MAKE-UP REMOVER L'OREAL (FR) 1988-05-11 EP disclosed
EP-0252732-A2 Transdermal drug delivery device ELAN TRANSDERMAL LIMITED (IE) 1988-01-13 EP disclosed
EP-0141732-A2 Cosmetic cleansing composition, particularly eye make-up remover L'OREAL (FR) 1985-05-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108730-A1 CORTICOSTEROID COMPOSITIONS NR3C1, SERPINA6, NR3C2 KDM4E 4286/4885ALDH1A1 2311/4885HSD17B10 278/4885
US-20230255984-A1 CORTICOSTEROID COMPOSITIONS NR3C1, SERPINA6, NR3C2 KDM4E 4286/4885ALDH1A1 2311/4885HSD17B10 278/4885
US-11357859-B2 Compositions for the treatment of gastrointestinal inflammation FABP2, FABP6, TNF KDM4E 4663/4885ALDH1A1 1302/4885HSD17B10 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.